RIVET TRIAL: PHASE 2 RCT OF RIFAMYCIN SV MMX, A NOVEL RIFAMPIN ANALOGUE, ON GUT-BRAIN AXIS CHANGES IN CIRRHOSIS AND MINIMAL HEPATIC ENCEPHALOPATHY
<div><p><strong>Background</strong>: Minimal hepatic encephalopathy (MHE) is associated with poor outcomes but treatment strategies are limited. Rifamycin SV MMX (RiVM) is a novel rifampin derivative which a non-absorbable antibiotic with maximal impact in the colon. <u>Aim</u>: Evaluate impact of RiVM on microbiome, safety & gut-brain axis in an RCT.</p>